Page 1699 - Clinical Small Animal Internal Medicine

Index 1637

intestinal cancers 1289–1290 SVT see supraventricular tachycardias bacterial pyodermas 1468–1469
VetBooks.ir mammary cancer 1322–1324 symmetric lupoid onychitis/ principles of therapy of dermatologic
swelling 461
miscellaneous skin diseases
male reproductive system
1497–1498, 1503
tumors 1312, 1314–1315
onychodystrophy (SLO)
mast cell tumors 1362, 1366 1505–1506, 1505 diseases 1399
melanoma 1348 sympathetic nervous system (SNS) systemic medications for hormonal
micturition and associated heart failure 179 disorders 1402
disorders 1184 systemic hypertension 219 systemic veins 121
nonmelanoma skin cancers 1356 valvular heart disease 245–246 systolic anterior motion of the mitral
ocular adnexal tumors 1263–1264 synbiotics 623–624 valve (SAM) 265, 268–269
oral tumors 1254, 1256 synchronized intermittent mandatory
orbital and optic nerve ventilation (SIMV) 394, 396, 401 t
tumors 1268 syncope T3/T4 see thyroid hormones
osteoarthritis 1535 canine myocardial disease 255, 264 tachycardia 405, 410, 448
pancreatic endocrine tumors 1298, cardiogenic shock 415 see also supraventricular
1300 cardiovascular disease 120–121 tachycardias; ventricular
papillomaviruses 863 congenital heart disease 240 tachycardia
pericardial disease 280–285, 283 valvular heart disease 246 tachypnea
pharyngeal tumors 1258 syndrome of inappropriate antidiuretic cardiogenic shock 416
pituitary‐dependent hormone secretion (SIADH) cardiovascular disease 120
hyperadrenocorticism 57, 62–63 1072–1073, 1072, 1214 feline bronchial asthma 297
plasma cell disorders 1245–1246 synovial cell sarcoma 1327 feline myocardial disease 270, 271
pleural effusion 342–343 synoviocentesis 1531 pleural effusion 338
portosystemic shunts and synthetic colloids 359–360, 409 respiratory pattern‐based approach
microvascular dysplasia 718 acute kidney injury 1095 to dyspnea 293, 295
prostatic diseases 1162 glomerular disease 1106 target organ damage (TOD)
rectoanal diseases 609–611, head trauma 755 219–221, 220, 223–224
613–614, 616–620 septic shock 426 TAT see tube agglutination test
respiratory pattern‐based approach systemic histiocytosis (SH) taurine deficiency
to dyspnea 291–292 1442–1443 canine myocardial disease 259
soft tissue sarcomas 1334–1337 systemic hypertension (HT) heart failure 188, 192
spinal cord injury 746–747, 219–224 metabolic diseases 678–679
746, 747 classifications 219 TB see tuberculosis
thoracotomy 325–330 diagnosis 221–222 T‐box transcription factor (Tpit) 51
ureteral obstruction 1120–1121, epidemiology 220 TBSA see total body surface area
1120–1121 etiology/pathophysiology TBW see total body water
urethral obstruction 1115–1117, 219–220, 220 TDI see tissue Doppler imaging
1116 history and clinical signs 221 TEG see thromboelastography
urinary tract tumors 1309–1310 patient selection and set‐up 221 telogen defluxion 1437
urolithiasis 1144, 1150–1151 prognosis 223–224 TEN see toxic epidermal necrolysis
surgical site infections signalment 220–221 tender loving care 352
(SSI) 1029–1032 target organ damage 219–221, 220, teratogenicity 1051
diagnosis 1030–1031, 1030–1031 223–224 testicular tumors 1311–1312, 1488
epidemiology 1029–1030 treatment and monitoring tetanus/tetany 967–968
etiology/pathophysiology 1029 222–223 diagnosis 968
history and clinical signs 1030 systemic inflammatory response epidemiology 967
nocosomial and multidrug‐resistant syndrome (SIRS) etiology/pathophysiology 967
infections 1058, 1060 Ebola virus 901 history and clinical signs
public health implications 1032 fluid therapy 358 967–968
signalment 1030 septic shock 421–422, 422, 425 hyperkinetic movement disorders
treatment and prognosis trauma and burns 445 768–769
1031–1032 systemic lupus erythematosus public health implications 968
suture‐induced urolithiasis (SLE) 542, 1487 signalment 967
1131, 1131–1132, 1144 systemic therapy treatment and prognosis 968